The ARTEMIS trial: Once-daily darunavir/ritonavir in the management of treatment-naive, HIV-infected patients

HIV Therapy

Volumn 3, Issue 2, 2009, Pages 121-133

  Cohen, Calvin J ^a  

^a Boston Community Research Initiative of New England   (United States)

Author keywords

Antiretroviral; ARTEMIS; Darunavir; Efficacy; HIV; Lopinavir; Protease inhibitor; Randomized, controlled trial; Treatment naive

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; TCM 114; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ALLERGY; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PREFERENCE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; JAUNDICE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MENTAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; NOTE; PATIENT COMPLIANCE; RASH; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 67149120656     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/17584310.3.2.121     Document Type: Note

References (43)

1. Hart E, Curtis H, Wilkins E, Johnson M: National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients. HIV Med. 8(3), 186-191 (2007). (Pubitemid 46915690)
2. Yuan Y, L'italien G, Mukherjee J, Iloeje UH: Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a USA HIV-infected patient cohort. HIV Med. 7(3), 156-162 (2006).
3. Kumarasamy N, Vallabhaneni S, Cecelia AJ et al.: Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J. Acquir. Immune Defic. Syndr. 41(1), 53-58 (2006).
4. Maggiolo F, Ripamonti D, Airoldi M et al.: Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. HIV Clin. Trials 8(1), 9-18 (2007). (Pubitemid 46542905)
5. Katlama C, Esposito R, Gatell JM et al.: Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 21(4), 395-402 (2007).
6. Haubrich R, Berger D, Chiliade P et al.: Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 21(6), F11-F18 (2007).
7. Clotet B, Bellos N, Molina JM et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369(9568), 1169-1178 (2007). •• Efficacy and safety of darunavir/ritonavir in treatment-experienced patients at 48 weeks, in comparison with currently available protease inhibitors in the Phase IIb POWER 1 and 2 trials. (Pubitemid 46541620)
8. Madruga JV, Berger D, McMurchie M et al.: Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled Phase III trial. Lancet 370(9581), 49-58 (2007). •• Efficacy and safety of darunavir/ritonavir in treatment-experienced, lopinavir-naive patients at 48 weeks, in comparison with lopinavir/ritonavir in the Phase III TITAN trial.
9. De Meyer S, Spinosa-Guzman S, Vangeneugden V, de Bethune MP, Miralles D: Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J. Acquir. Immune Defic. Syndr. 49(2), 179-182 (2008). • Treatment-experienced, HIV-infected patients with no baseline darunavir resistance-associated mutations (RAMs) achieved similar high responses with darunavir/ritonavir 800/100 mg once daily and 600/100 mg twice daily, suggesting that once-daily darunavir/r 800/100 mg therapy shows potential in patients with no darunavir RAMs.
10. Ortiz R, DeJesus E, Khanlou H et al.: Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22(12), 1389-1397 (2008). •• Efficacy and safety of darunavir/ritonavir 800/100mg once daily in comparison with lopinavir/ritonavir in treatment-naive patients in the Phase III ARTEMIS trial at 48 weeks.
11. Sekar V, Spinosa-Guzman S, Lefebvre E, Hoetelmans R: Clinical pharmacology of TMC114 - a new HIV protease inhibitor. Presented at: 16th International AIDS Conference. Toronto, Ontario, Canada, 13-18 August 2006 (Abstract TUPE0083).
12. Dierynck I, De Meyer S, Lathouwers E et al.: Comparable virological outcome to DRV/r in pts infected with subtype B and non-B HIV isolates participating in the ARTEMIS trial. Presented at: The XVII International drug Resistance Workshop. Stiges, Spain, 10-14 June 2008 (Abstract 125).
13. Paterson DL, Swindells S, Mohr J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133(1), 21-30 (2000). (Pubitemid 30432540)
14. Mills AM, Chetchotisakd P, DeMasi R et al.: Adherence to darunavir/ritonavir and lopinavir/ritonavir in treatment-naive HIV patients in ARTEMIS. Presented at: Frontiers in Drug Development for Antiretroviral Therapies (DART). Rio Grande, Puerto Rico, 9-12 December 2008 (Abstract 61). • Assessment of response by adherence to treatment in ARTEMIS, where nonadherence to lopinavir/ritonavir compromised virologic response more than nonadherence to darunavir/ritonavir.
15. Johnson VA, Brun-Vezinet F, Clotet B et al.: Update of the drug resistance mutations in HIV-1: Fall 2006. Top. HIV Med. 14(3), 125-130 (2006).
16. Pertel P, Hirschtick R: Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 18(4), 630-632 (1994). (Pubitemid 24106920)
17. Sekar V, Vanden Abeele C, Van Baelen B et al.: Pharmacokinetic- pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 769).
18. Molina JM, Andrade-Villanueva J, Echevarria J et al.: Efficacy and safety of once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects: the CASTLE Study, 48-week results. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 37).
19. Eron J Jr, Yeni P, Gathe J Jr et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368(9534), 476-482 (2006). (Pubitemid 44160731)
20. Walmsley S, Ruxrungtham K, Slim J, Ward D, Larson P, Raffi F: Saquinavir/r (SQV/r) bid versus lopinavir/r (LPV/r) bid, plus emtricitabine/tenofovir (FTC/TDF) qd as initial therapy in HIV-1-infected patients: the Gemini Study. Presented at: 11th European AIDS Conference. Madrid, Spain, 24-27 October 2007 (Abstract PS1/4).
21. Kempf DJ, King MS, Bernstein B et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189(1), 51-60 (2004). (Pubitemid 38122329)
22. Zazzi M: Lack of major resistance mutations in HIV-1 protease at failure of boosted protease inhibitor-based first-line antiretroviral treatment. Rev. Antiviral. Ther. 2, 4-12 (2007).
23. De Meyer S, Lathouwers E, Dierynck I et al.: Characterization of virological failures on darunavir/ritonavir in the randomized, controlled, Phase III TITAN trial in treatment-experienced patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 874).
24. Delfraissy JF, Flandre P, Delaugerre C et al.: MONARK trial (MONotherapy Antiretroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared with LPV/r + zidovudine/ lamivudine (AZT/3TC) in antiretroviralnaive patients. Presented at: 16th International AIDS Conference. Toronto, Ontario, Canada, 13-18 August 2006 (Abstract THLB0202).
25. Cozzi-Lepri A, Phillips AN, Ruiz L et al.: Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 21(6), 721-732 (2007). (Pubitemid 46568629)
26. + cell counts and HIV RNA levels during follow-up. J. Infect. Dis. 197(8), 1145-1155 (2008).
27. Mildvan D, Tierney C, Gross R et al.: Randomized comparison in treatment-naive patients of once-daily vs twice-daily lopinavir/ritonavir-based ART and comparison of once-daily self-administered vs directly observed therapy. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007 (Abstract 138).
28. Gathe J Jr, da Silva B, Loutfy MR et al.: Study M05-730 primary efficacy results at week 48: Phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir DF + emtricitabine in ARV-naive HIV-1-infected subjects. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 775).
29. Cameron DW, da Silva B, Arribas J et al.: A two-year randomized controlled clinical trial in antiretroviral-naive subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared with an efavirenz (EFV) 3-drug regimen (Study M03-613). Presented at: 16th International AIDS Conference. Toronto, Ontario, Canada, 13-18 August 2006 (Abstract THLB0201).
30. Arribas J, Pulido F, Delgado R et al.: Lopinavir/ritonavir as single-drug therapy in patients with HIV-1 viral suppression: 48 week results of a randomized, controlled trial. Presented at: 16th International AIDS Conference. Toronto, Ontario, Canada, 13-18 August 2006 (Abstract THLB0203).
31. Nunes E, Oliveira M, Almeida M et al.: 48-week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/ml on HAART - the KalMo study. Presented at: 16th International AIDS Conference. Toronto, Ontario, Canada, 13-18 August 2006 (Abstract TUAB0103).
32. Ortiz R, DeJesus E, Khanlou H et al.: Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at Week 48. AIDS 22(12), 1389-1397 (2008).
33. USA Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 3 November 2008 (Accessed 9 February 2009). http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf
34. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV-infected adults in Europe; version 3 June 2008 (Accessed 7 October 2008). www.eacs.eu/guide/index.htm
35. Tibotec Inc. PREZISTA™ (darunavir) prescribing information (Accessed 7 October 2008). www.prezista.com/prezista/documents/us-package- insert.pdf
36. PREZISTATM (darunavir) summary of product characteristics (Accessed 7 October 2008). www.emea.europa.eu/humandocs/humans/EPAR/prezista/prezista.htm
37. AIDS Clinical Trials Group. Division of AIDS table for grading the severity of adult and pediatric events (Accessed 7 October 2008). http://rcc.techres.com/DAIDS%20RCC%20 Forms/TB-ToxicityTables-DAIDS-AE- GradingTable-FinalDec2004.pdf
38. Abbott Laboratories. Kaletra® (lopinavir/ritonavir) prescribing information (Accessed 7 October 2008). www.kaletra.com
39. Bristol-Myers Squibb Co. Reyataz® (atazanavir sulfate) prescribing information (Accessed 7 October 2008). www.ucdmc.ucdavis.edu/clinicaltrials/ documents/DAIDS-AE-GradingTable-FinalDec2004.pdf
40. GlaxoSmithKline. AGENERASE. USA Food and Drug Administration guidance document (Accessed 9 February 2009). www.fda.gov/CDER/drug/shortages/AGN- DC%20DHP%20Letter.pdf
41. GlaxoSmithKline. LEXIVA® (fosamprenavir calcium) prescribing information (Accessed 7 October 2008). www.lexiva.com
42. Merck & Co Inc. CRIXIVAN® (indinavir sulfate) prescribing information (Accessed 7 October 2008). www.crixivan.com/indinavir-sulfate/ crixivan/consumer/product-information/pi/index.jsp
43. Tibotec. Prezista® (darunavir) USA prescribing information (Accessed 7 October 2008). www.tibotectherapeutics.com/tibotectherapeutics/documents/us- package-insert.pdf